Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update Interim Clinical Study Results for Cohort 1 of the BB-301 Phase 1b/2a Treatment Study Anticipated in Q4 2025 Enrollment of the First Subject into Cohort 2 of the BB-301 Phase 1b/2a Treatment Study Expected in Q4 2025 For the year ended June 30, 2025, the Company reported total expenses of $41.8 million compared to$22.5 million for the year ended June 30, 2024. Royalties and license fees were $0 in 2025, compared to ...